Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2024 09:00 ET | Source: Longeveron

Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
August 26, 2024 16:05 ET | Source: Longeveron

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron to present at HC Wainwright global investment conference.
August 14, 2024 16:05 ET | Source: Longeveron

Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update

Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
August 05, 2024 16:05 ET | Source: Longeveron

Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

Longeveron announced that it will report Q2 2024 financial results and provide a business update on Wednesday, August 14, 2024.
July 28, 2024 16:51 ET | Source: Longeveron

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
July 19, 2024 16:05 ET | Source: Longeveron

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron announces closing of previously announced registered direct offering, raising $9 million in gross proceeds.
July 18, 2024 08:45 ET | Source: Longeveron

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron announces $9.0 million registered direct offering.
July 17, 2024 08:00 ET | Source: Longeveron

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron announces FDA has granted Fast Track designation to cellular therapy Lomecel-B(TM) for the treatment of mild Alzheimer’s Disease.
July 10, 2024 07:30 ET | Source: Longeveron

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
July 09, 2024 09:00 ET | Source: Longeveron

Neha Motwani Elected to Longeveron® Board of Directors

Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right